Clinical Trial Search

Primary: Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16…

Primary: Percentage of Participants With Greater Than or Equal to (≥) 0.2 Reduction of BMI Z-Score From Baseline to Week 52 — 85.7; 80.0 percentage of participants

Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity(AUC0-inf) for Part 1 — 2200; 2598; 2878; 2675 h*ng/mL

Primary: Number of Participants With an Improvement of Greater Than or Equal to (>=) 4 From Baseline in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16…

Primary: Clinical Cure — 7; 10; 23 Participants

Primary: Residual Beta-cell Function (RBCF) — 1.78; 2.27; 1.56; 1.76 ng/ml — p=<0.001

Primary: Percent Change in Coughing Episodes Per Day From Baseline to Day 21. — -73.2; -16.1 % change in coughing episodes — p=0.0001

Primary: Percentage of Participants Who Achieved Confirmed Clearance of Plasma CMV Deoxyribose Nucleic Acid (DNA) at Week 8 — 68.3 percentage of participants

Primary: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST…

Primary: Change in Dose of Calcium Supplementation — 37 percent change in dose

Primary: Primary Feasibility Outcome - Number of Participants Recruited Per Month — 7.5; 2.0 Average enrolment rate/month/site

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 7; 2; 7; 2 Participants

Primary: Number of Deaths — 131; 158 Participants

Primary: Number of New BCCs Per Participant — 2.84; 4.03 New basal cell carcinomas

Primary: Percentages of Participants With a 4-fold Rise in Human Serum Bactericidal Assay (hSBA) Titers Against N. Meningitidis Serogroups A, C, W, and Y at 1 Month After the…